$2.58
+0.04 (+1.57%)
Open$2.72
Previous Close$2.54
Day High$2.72
Day Low$2.53
52W High$20.59
52W Low$2.45
Volume—
Avg Volume31.2K
Market Cap11.97M
P/E Ratio—
EPS$-10.38
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+1,500.0% upside
Current
$2.58
$2.58
Target
$41.28
$41.28
$32.58
$41.28 avg
$58.47
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.64M | 1.62M | 1.37M |
| Net Income | -247,177 | -249,222 | -229,259 |
| Profit Margin | -15.1% | -15.4% | -16.8% |
| EBITDA | -331,691 | -310,875 | -283,649 |
| Free Cash Flow | -127,219 | -197,557 | -123,470 |
| Rev Growth | +20.7% | +12.0% | +3.1% |
| Debt/Equity | 0.09 | 0.11 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |